Atossa Therapeutics’ (ATOS) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS) in a research report report published on Friday morning, Benzinga reports. They currently have a $6.00 target price on the stock.

Several other equities research analysts have also issued reports on the stock. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $6.00 to $6.25 and gave the stock a buy rating in a report on Thursday, June 6th. Cantor Fitzgerald reiterated an overweight rating on shares of Atossa Therapeutics in a report on Thursday, June 20th. Finally, StockNews.com upgraded Atossa Therapeutics from a sell rating to a hold rating in a report on Tuesday, May 14th.

Atossa Therapeutics Trading Up 4.4 %

ATOS opened at $1.19 on Friday. The stock has a 50-day moving average of $1.39 and a 200 day moving average of $1.22. Atossa Therapeutics has a 12 month low of $0.62 and a 12 month high of $2.31. The firm has a market cap of $149.65 million, a P/E ratio of -4.96 and a beta of 1.19.

Atossa Therapeutics (NASDAQ:ATOS) last announced its earnings results on Monday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.02. On average, research analysts forecast that Atossa Therapeutics will post -0.23 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Jonathan Finn acquired 25,000 shares of the company’s stock in a transaction that occurred on Wednesday, April 10th. The shares were bought at an average price of $1.77 per share, with a total value of $44,250.00. Following the completion of the purchase, the director now directly owns 25,000 shares in the company, valued at $44,250. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.60% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. PFG Investments LLC purchased a new stake in shares of Atossa Therapeutics in the 1st quarter worth approximately $43,000. Cetera Advisors LLC purchased a new stake in Atossa Therapeutics during the first quarter worth $72,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in Atossa Therapeutics during the 3rd quarter valued at $98,000. Virtu Financial LLC purchased a new position in shares of Atossa Therapeutics in the 1st quarter valued at $151,000. Finally, Vanguard Group Inc. raised its position in shares of Atossa Therapeutics by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 5,753,993 shares of the company’s stock worth $10,357,000 after acquiring an additional 78,269 shares in the last quarter. 12.74% of the stock is currently owned by institutional investors.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.